

## BOARD OF DIRECTORS

**Samuel Arce, MD, FAAP**

*Chairman*

Family Physician and Attending Physician  
Jamaica Hospital Medical Center, Jamaica, NY

**Elena Rios, MD, MSPH**

*President & CEO*

National Hispanic Medical Association,  
Washington, DC

**Ana Maria Lopez, MD, MPH, FACP**

*Secretary*

Associate Vice President for Health  
Equity and Inclusion, University of Utah  
Health Sciences Center, Director of Cancer  
Health Equity, Huntsman Cancer Institute,  
Professor of Medicine, University of Utah  
School of Medicine, Salt Lake City, Utah

**Nelson Reyneri**

*Treasurer*

Vice President, Sales and External Affairs  
Liberty Power, Fort Lauderdale, FL

**Judith Flores, MD, FAAP, CHQM**

*Chairwoman-Elect*

Clinical Associate Professor  
New York University School of Medicine  
New York, NY

**Katherine A. Flores, MD**

*Immediate-Past Chairwoman*

Director, UCSF-Fresno, Latino Center for  
Medical Education & Research, Fresno, CA

**David Carlisle, MD, PhD**

*President and CEO*

Charles R. Drew University of Medicine  
& Biomedical Sciences, Los Angeles, CA

**Nerieda Correa, MD**

Eastchester Medical Associates, PC, Bronx, NY

**Efrain Fuentes, EDD**

Los Angeles, CA

**Jorge A. Girotti, PhD, MA**

Associate Dean and Director, Special Curricular  
Programs, Admissions, Hispanic Center of Excellence  
Assistant Professor, Medical Education  
UIC College of Medicine, Chicago IL

**Antonio Linares, MD**

Medical Director and Regional VP, Anthem Blue Cross  
Health & Wellness Solutions, Indianapolis, IN

**Flavia E. Mercado, MD**

Medical Director, Inovalon, Inc.  
Adjunct Professor, Snelville, GA

**Jorge G. Puente, MD**

Managing Partner  
Pleasanton Pharma Ventures, Northport, NY

**Diana Ramos, MD, MPH**

Director, Reproductive Health, Los Angeles County  
Public Health, Laguna Beach, CA

**Vanessa Saucedo, MD, MPH, FAAP**

Chairwoman, NHMA Council of Young Physicians  
Union Community Health Center, New York, NY

**Minerva Romero-Arenas, MD, MPH**

Chairwoman, NHMA Council of Residents  
General Surgery Resident, Sinai Hospital  
Baltimore, MD

**Eric Molina**

President, Latino Medical Student Association  
Baylor College of Medicine, Houston, TX

**Minerva Campos, MD, MPH**

Washington, DC

**Carlos Corral, MD, FACS**

New Mexico Cardiovascular Associates  
Las Cruces, NM

**Claudia H. Zamora, MPA**

Manager, PricewaterhouseCoopers, LLP  
Washington, DC

## ADVISORY COUNCIL

**Richard H. Carmona, MD, MPH, FACS**

17<sup>th</sup> US Surgeon General (2002-2006)  
Vice Chairman, Canyon Ranch Institute  
Distinguished Professor, Zuckerman College of  
Public Health, University of Arizona, Tucson, AZ

**Henry Cisneros**

Chairman, CityView, San Antonio, TX

**Ivelisse Estrada**

Senior Vice President for Corporate and  
Community Relations, Univision, Los Angeles, CA

**Linda Griego**

President & CEO, Griego Enterprises, Inc.  
Los Angeles, CA

**Paloma Hernandez**

President and CEO Urban Health Plan, Inc.  
Bronx, NY

**Yasmine Winkler**

Senior VP Innovation and Productivity  
United HealthCare, Chicago, IL

**Richard Zapanta, MD**

Orthopedic Surgeon, Monterey Park, CA



February 3, 2017

Senator David Wilson

Chair, Senate Health & Social Services Committee

Senator Mia Costello

Chair, Senate Labor & Commerce Committee

Alaska State Capitol

Juneau, AK 99801

Senator Wilson and Senator Costello:

On behalf of the Board of Directors of the National Hispanic Medical Association, we urge you to vote yes for SB 32, FDA-designated interchangeable biological drug products.

These bills authorize a pharmacist to substitute an alternative biological product when filling a prescription for a prescribed biological product if the alternative biological products is designated as interchangeable with the reference product and communication is provided to the patient and physician that a substitution was made. These bills would also require that the substitution of a biological product be communicated to the patient.

We recognize the rising use of biologics and biosimilars in our population now aging with increased chronic disease. Biosimilars go through an extensive review process and manufacturers are required to submit immense studies and data demonstrating a products' efficacy and ensuring it is safe for use by consumers. A pathway for biosimilar regulation in the U.S. was established as a provision of the 2008 Patient Protection and Affordable Care Act (ACA) and in 2012 the FDA issued draft guidelines for biosimilars and a list of biosimilars and interchangeable biological products.

In summary, the National Hispanic Medical Association recommends your support for SB 32 before the end of session to clarify the procedures for biosimilar substitution for biologic treatments in a way that increases safety for the patient. We are especially supportive since these bills will provide increased access to quality treatment for Hispanics and all persons from Alaska with chronic diseases.

Sincerely,

Elena Rios, MD, MSPH, FACP  
President & CEO